Alsarraf E, Myers J, Culbreth S, Fanikos J (2019) Kratom from head to toe—case reviews of adverse events and toxicities. Curr Emerg Hosp Med Rep 7:141–168

Article  Google Scholar 

Barratt ES (1993) Impulsivity: Integrating cognitive, behavioral, biological, and environmental data

Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri CA, Grundmann O (2020) Self-reported Health diagnoses and demographic correlates with Kratom Use: results from an online survey. J Addict Med 14:244–252

Article  PubMed  PubMed Central  Google Scholar 

Bremner J (2014) The clinician administered dissociative states scale (CADSS): instructions for administration. Emory University

Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered Dissociative States Scale (CADSS). J Trauma Stress 11:125–136

Article  CAS  PubMed  Google Scholar 

Brogdon HD, McPhee MM, Paine MF, Cox EJ, Burns AG (2022) A case of potential pharmacokinetic kratom-drug interactions resulting in toxicity and subsequent treatment of Kratom Use Disorder with Buprenorphine/Naloxone. J Addict Med

Cairns ED, Cammock T (1978) Development of a more reliable version of the matching familiar figures test. Dev Psychol 14:555

Article  Google Scholar 

Chin KY, Mark-Lee WF (2018) A review on the Antinociceptive effects of Mitragyna Speciosa and its derivatives on animal model. Curr Drug Targets 19:1359–1365

Article  CAS  PubMed  Google Scholar 

Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li JH, Yu WJ, Kapitány-Fövény M, Farkas J, Di Giannantonio M, Corazza O (2015) Following the Roots of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. Biomed Res Int 2015: 968786

Clare S, Helps S, Sonuga-Barke EJ (2010) The quick delay questionnaire: a measure of delay aversion and discounting in adults. Attention deficit and hyperactivity disorders, vol 2. 43– 8

Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE (2019) Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend 202:24–32

Article  CAS  PubMed  Google Scholar 

Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A (2019) Characteristics of deaths associated with kratom use. J Psychopharmacol 33:1102–1123

Article  PubMed  Google Scholar 

Daigre Blanco C, Ramos-Quiroga JA, Valero S, Bosch R, Roncero C, Gonzalvo B, Nogueira M (2009) Adult ADHD self-report scale (ASRS-v1.1) symptom checklist in patients with substance use disorders. Actas Esp De Psiquiatria 37:299–305

Google Scholar 

de Wit H, Enggasser JL, Richards JB (2002) Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27:813–825

Article  PubMed  Google Scholar 

Derogatis L (1975) Brief symptom inventory (Baltimore, clinical psychometric research). Psychopathology 27:14–18

Google Scholar 

Derogatis LR (1993) BSI brief symptom inventory. Administration, scoring, and procedures manual

Derogatis LR, Melisaratos N (1983) The brief Symptom Inventory: an introductory report. Psychol Med 13:595–605

Article  CAS  PubMed  Google Scholar 

Feldman JD, Schriefer D, Smith KE, Weiss ST, Butera G, Dunn KE, Grundmann O, McCurdy CR, Singh D, Epstein DH (2023) Omissions, ambiguities, and Underuse of Causal Assessment Tools: a systematic review of Case reports on patients who use Kratom. Curr Addict Rep 10:293–303

Article  Google Scholar 

Grundmann O (2017) Patterns of Kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend 176:63–70

Article  PubMed  Google Scholar 

Grundmann O, Veltri CA, Morcos D, Knightes D 3rd, Smith KE, Singh D, Corazza O, Cinosi E, Martinotti G, Walsh Z, Swogger MT (2022) Exploring the self-reported motivations of kratom (Mitragyna Speciosa Korth.) Use: a cross-sectional investigation. Am J Drug Alcohol Abuse 48:433–444

Grundmann O, Hill K, Al Barzanji E, Hazrat NG, Kaur G, Negeve RE, Shade S, Weber S, Veltri CA (2023) Correlations of kratom (Mitragyna Speciosa Korth.) Tea bag preparations and reported pharmacological effects. J Ethnopharmacol 317:116779

Article  CAS  PubMed  Google Scholar 

Haertzen CA, Hill HE, Belleville RE, DEVELOPMENT OF THE ADDICTION RESEARCH CENTER INVENTORY (ARCI) (1963) SELECTION OF ITEMS THAT ARE SENSITIVE TO THE EFFECTS OF VARIOUS DRUGS. Psychopharmacologia 4:155–166

Article  CAS  PubMed  Google Scholar 

Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NI, Jayabalan N, Hazim AI, Mansor SM, Müller CP (2013) From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev 37:138–151

Article  CAS  PubMed  Google Scholar 

Hassan Z, Suhaimi FW, Ramanathan S, Ling KH, Effendy MA, Müller CP, Dringenberg HC (2019) Mitragynine (Kratom) impairs spatial learning and hippocampal synaptic transmission in rats. J Psychopharmacol 33:908–918

Article  CAS  PubMed  Google Scholar 

Henningfield JE, Grundmann O, Huestis MA, Smith KE (2024) Kratom safety and toxicology in the public health context: research needs to better inform regulation. Front Pharmacol 15

Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the internet. Subst Use Misuse 45:330–340

Article  PubMed  Google Scholar 

Hiranita T, Obeng S, Sharma A, Wilkerson JL, McCurdy CR, McMahon LR (2022) In vitro and in vivo pharmacology of kratom. Adv Pharmacol 93:35–76

Article  CAS  PubMed  Google Scholar 

Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45:462–471

Article  CAS  PubMed  Google Scholar 

Huestis MA, Brett MA, Bothmer J, Atallah R (2024) Human mitragynine and 7-Hydroxymitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried Kratom Leaf Powder. Molecules 29:984

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jaeger J (2018) Digit symbol substitution test: the case for Sensitivity over specificity in Neuropsychological Testing. J Clin Psychopharmacol 38:513–519

Article  PubMed  PubMed Central  Google Scholar 

Johnson LE, Balyan L, Magdalany A, Saeed F, Salinas R, Wallace S, Veltri CA, Swogger MT, Walsh Z, Grundmann O (2020) The potential for Kratom as an antidepressant and Antipsychotic. Yale J Biol Med 93:283–289

CAS  PubMed  PubMed Central  Google Scholar 

Kruegel AC, Grundmann O (2018) The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology 134:108–120

Article  CAS  PubMed  Google Scholar 

Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D (2016) Synthetic and receptor signaling explorations of the Mitragyna alkaloids: Mitragynine as an atypical Molecular Framework for opioid receptor modulators. J Am Chem Soc 138:6754–6764

Article  CAS  PubMed  PubMed Central  Google Scholar 

La-Up A, Saengow U, Aramrattana A (2021) High serum high-density lipoprotein and low serum triglycerides in Kratom users: a study of Kratom users in Thailand. Heliyon 7:e06931

Article  CAS  PubMed  PubMed Central  Google Scholar 

La-Up A, Wongrith P, Chaichan W, Aramrattana A, Saengow U (2022) Association between Kratom (Mitragyna Speciosa) use and metabolic syndrome. Heliyon 8:e09468

Article  PubMed  PubMed Central  Google Scholar 

Lamers MJ, Roelofs A, Rabeling-Keus IM (2010) Selective attention and response set in the Stroop task. Mem Cognit 38:893–904

Article  PubMed  Google Scholar 

León F, Obeng S, Mottinelli M, Chen Y, King TI, Berthold EC, Kamble SH, Restrepo LF, Patel A, Gamez-Jimenez LR, Lopera-Londoño C, Hiranita T, Sharma A, Hampson AJ, Canal CE, McMahon LR, McCurdy CR (2021) Activity of Mitragyna Speciosa (Kratom) alkaloids at serotonin receptors. J Med Chem 64:13510–13523

Article  PubMed  PubMed Central  Google Scholar 

Leong Abdullah MFI, Tan KL, Narayanan S, Yuvashnee N, Chear NJY, Singh D, Grundmann O, Henningfield JE (2021) Is kratom (Mitragyna Speciosa Korth.) Use associated with ECG abnormalities? Electrocardiogram comparisons between regular kratom users and controls. Clin Toxicol (Phila) 59:400–408

Article  CAS  PubMed  Google Scholar 

Leong Bin Abdullah MFI, Singh D (2021) Assessment of Cardiovascular Functioning among regular Kratom (Mitragyna Speciosa Korth) users: a Case Series. Front Pharmacol 12:723567

Article  PubMed  PubMed Central  Goog